Meet Polyplus during the Buzz4Bio in Brussels, Belgium on 12th - 13th March 2024. Dont miss the opportunity to hear our talk by our expert Sylvain Julien on how to ramping up the AAV manufacturing : existing and upcoming solutions from Polyplus.

Our team

BUZZ4BIO brings together major players in the biotech industry for dynamic exchanges and networking opportunities. With its stimulating conferences and innovative pitch sessions, Buzz4bio offers a unique platform for promoting technological advances and collaborations in Cellular and Gene Therapies. Participants can discover the latest trends, helps to increase scalability of processes and accessibility to biotherapies, share innovative ideas, and establish strategic partnerships to shape the future of biotechnology.



    Sylvain Julien Ph.D., Innovation Director e-Zyvec at Polyplus®. 

Talk : Ramping up the AAV manufacturing : existing and upcoming solutions from Polyplus | Wednesday 13 March, 12:30 PM

Talk Summary : The advancement of AAV-based gene therapy hinges on the affordability of therapeutic doses. One way to reach this economical soundness is to reduce manufacturing costs by increasing production yields. As Polyplus, we have a historical track record in proposing performant polymers for enhanced transfection rate. We have also recently integrated world class expertise in the plasmid prototyping and manufacturing domain. Today we are proposing both innovative transfection reagents and innovative plasmid products and services that are improving AAV production yields and can be combined for cumulative effect. Our expertise means that we can support your projects from the early stages of discovery right through to industrial production. Tomorrow, as part of Sartorius, we will be able to offer our customers access to a complete range of services to guarantee successful drug development.

Discover Our Applications

Cell & Gene Therapy

Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering

RNA/DNA Therapeutics

RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies

Protein Production

Broad range of solutions is needed for manufacturing of functional  proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems

Life Sciences

Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types